S
Suzanne Vento
Researcher at North Shore-LIJ Health System
Publications - 31
Citations - 1056
Suzanne Vento is an academic researcher from North Shore-LIJ Health System. The author has contributed to research in topics: Focal segmental glomerulosclerosis & Nephrology. The author has an hindex of 14, co-authored 30 publications receiving 917 citations. Previous affiliations of Suzanne Vento include Boston Children's Hospital & Albert Einstein College of Medicine.
Papers
More filters
Journal ArticleDOI
Urolithiasis in Pediatric Patients: A Single Center Study of Incidence, Clinical Presentation and Outcome
Kristy VanDervoort,Jonathan Wiesen,Rachel M. Frank,Suzanne Vento,Virginia Crosby,Manju Chandra,Howard Trachtman +6 more
TL;DR: The incidence of urolithiasis in the pediatric population increased nearly 5-fold at this institution during the last decade, and it is recommended that the primary diagnostic test be a 24-hour urine collection.
Journal ArticleDOI
Clinical trial of focal segmental glomerulosclerosis in children and young adults
Debbie S. Gipson,Howard Trachtman,Frederick J. Kaskel,Tom Greene,Milena Radeva,Jennifer J. Gassman,Marva Moxey-Mims,Ronald J. Hogg,Sandra L. Watkins,Richard N. Fine,Susan L. Hogan,John P. Middleton,V. Matti Vehaskari,Patti A. Flynn,Leslie M. Powell,Suzanne Vento,June L. McMahan,Norman J. Siegel,Vivette D. D'Agati,Aaron L. Friedman +19 more
TL;DR: This study did not find a difference in rates of proteinuria remission following 12 months of cyclosporine compared to mycophenolate/dexamethasone in patients with steroid-resistant FSGS, however, the small sample size might have prevented detection of a moderate treatment effect.
Journal ArticleDOI
Urinary exosomal Wilms' tumor-1 as a potential biomarker for podocyte injury.
Hua Zhou,Hua Zhou,Hiroshi Kajiyama,Takayuki Tsuji,Xuzhen Hu,Asada Leelahavanichkul,Suzanne Vento,Rachel M. Frank,Jeffrey B. Kopp,Howard Trachtman,Robert A. Star,Peter S.T. Yuen +11 more
TL;DR: Urinary exosomal WT-1 is a promising noninvasive biomarker with apparent podocyte specificity that can detect early progression and treatment-induced regression of podocytes injury in FSGS or SSNS and warrant longitudinal, prospective studies in a large cohort with a range of podocyte diseases.
Journal ArticleDOI
Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group
Melanie S. Joy,Debbie S. Gipson,Leslie M. Powell,Jacqueline MacHardy,J. Charles Jennette,Suzanne Vento,Cynthia G. Pan,Virginia J. Savin,Allison A. Eddy,Agnes B. Fogo,Jeffrey B. Kopp,Daniel C. Cattran,Howard Trachtman +12 more
TL;DR: Pharmacokinetic assessment showed increased clearance of adalimumab in patients with resistant primary FSGS and validated the need to evaluate the disposition of novel therapies for this disease to define appropriate dosing regimens.
Journal ArticleDOI
Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome
TL;DR: The findings indicate that mycophenolate mofetil is a useful adjunctive therapy in the treatment of patients with steroid-dependent nephrotic syndrome, and lowers the relapse rate by 40% and is well tolerated by patients.